Dr. Lal Path Labs
3,108.10
-48.60(-1.54%)
Market Cap₹26,445.40 Cr
PE Ratio50.26
Company Performance:
1D-1.54%
1M-4.70%
6M+14.52%
1Y-6.18%
5Y+46.27%
View Company Insightsright
More news about Dr. Lal Path Labs
31Jul 25
Dr. Lal PathLabs Posts 18% Surge in Q1 Net Profit, Declares Interim Dividend
Dr. Lal PathLabs announced robust Q1 2025-26 financial results, with net profit increasing by 18% to ₹1.30 billion and revenue rising 11.70% to ₹6.70 billion. The company declared an interim dividend of ₹6 per equity share. Operational updates include the completion of voluntary liquidation of Suburban Diagnostics and dissolution of Dr. Lal PathLabs Kenya Private Limited.
24Jul 25
Dr. Lal PathLabs Gears Up for Q1 FY26 Earnings Call, Board to Consider Interim Dividend
Dr. Lal PathLabs Ltd., a leading Indian diagnostic services provider, will hold its Q1 FY26 earnings conference call on July 31, 2025, at 4:30 PM IST. The call will discuss financial and operating performance for the quarter ended June 30, 2025. Key leadership, including Executive Chairman Dr. Arvind Lal, CEO Shankha Banerjee, and Group CFO Ved Prakash Goel, will participate. The company operates 298 clinical labs, 6,607 Patient Service Centers, and 12,365 Pick-up Points as of March 31, 2025. In FY2025, it processed 86 million samples from 28.80 million patients. The board will consider a potential interim dividend during the meeting.
25Jun 25
Dr. Lal PathLabs Boosts Genomics Capabilities with Cutting-Edge Illumina Technology
Dr. Lal Path Labs has acquired Illumina's NovaSeq X Series technology to boost its genetic testing and analysis services. This advanced equipment is expected to improve turnaround times, increase testing capacity, enhance accuracy in detecting genetic variations, and expand the range of genomic services offered. The move aligns with the trend towards personalized medicine and strengthens the company's position in the diagnostics market.
29Apr 25
Dr Lal PathLabs Sets Ambitious Growth Targets, Plans Expansion Across India
Dr Lal PathLabs announces plans to achieve a 27% margin by FY26, with expansion plans including 15-20 new laboratories focusing on southern and western India. The company reported impressive Q4 results with revenue up 10.50%, EBITDA up 17%, and net profit surging 81.20% year-over-year. The board recommended a final dividend of Rs 6.00 per share for FY25.
25Apr 25
Dr. Lal PathLabs Q4 Profit Soars 83%, Surpasses Expectations
Dr. Lal PathLabs Limited posted strong Q4 FY25 results with net profit up 83% YoY to Rs 154.80 crore, outpacing revenue growth of 10.5% to Rs 602.60 crore. EBITDA grew 17% to Rs 169.00 crore with improved margin of 28%. For FY25, revenue increased 10.50% to Rs 24,614.00 crore, while net profit rose 35.90% to Rs 4,922.00 crore. The company announced a final dividend of Rs 6.00 per share, bringing the total FY25 dividend to Rs 24.00 per share.
15Apr 25
Dr. Lal PathLabs Pioneers Advanced Amyloidosis Test in South Asia
Dr. Lal PathLabs has become the first diagnostic chain in South Asia to launch an advanced test for amyloidosis, a group of rare diseases characterized by abnormal protein buildup in organs. This breakthrough enhances early detection and management capabilities for these complex disorders. The introduction of this test demonstrates Dr. Lal PathLabs' commitment to innovation and could strengthen its market position in the diagnostic industry.
07Apr 25
Dr. Lal Path Labs Witnesses Significant Block Trade on NSE
A significant block trade of 101,444 shares of Dr. Lal Path Labs Ltd. occurred on the National Stock Exchange. The shares were traded at Rs. 2,448.00 each, totaling Rs. 24.83 crore. While the identities of the buyer and seller remain undisclosed, such large transactions often indicate strategic moves by institutional investors or major shareholders.
02Apr 25
Dr. Lal PathLabs Witnesses Substantial Block Trade on NSE
A significant block trade of Dr. Lal PathLabs Ltd. shares occurred on the National Stock Exchange (NSE). The transaction involved 593,348 shares at ₹2,406.50 per share, totaling ₹142.79 crore. This large-scale trade could potentially impact the company's short-term trading patterns and may indicate shifts in ownership or strategy among major investors.
05Mar 25
Dr. Lal PathLabs Sees Major Block Trade Worth ₹54.54 Crore on NSE
A significant block trade of approximately 227,175 shares of Dr. Lal PathLabs Ltd. occurred on the National Stock Exchange. The shares were traded at ₹2,400.75 each, totaling a transaction value of ₹54.54 crore. This large-scale trade has drawn market attention, potentially signaling shifts in institutional or large investor holdings.
27Feb 25
Dr. Lal Path Labs Witnesses Significant Block Trade on NSE
A significant block trade of 116,643 shares of Dr. Lal Path Labs Ltd. occurred on the NSE, valued at Rs. 27.26 crores. The average price per share was Rs. 2,336.95. This large transaction could potentially impact the stock's trading pattern in the short term.
Dr. Lal Path Labs
3,108.10
-48.60
(-1.54%)
1 Year Returns:-6.18%
Industry Peers
Dr. Lal Path Labs
3,108.10
(-1.54%)
Metropolis Healthcare
1,938.20
(-0.61%)
Thyrocare Technologies
1,243.90
(-2.49%)
Krsnaa Diagnostics
779.10
(-4.38%)
Suraksha Diagnostic
300.55
(+0.13%)
3B BlackBio DX
1,378.00
(+0.52%)
Sastasundar Ventures
305.30
(-1.52%)
Choksi Laboratories
163.30
(-3.32%)